ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Sodium triacetoxyborohydride → 4-(8-((2,2-dimethyl-4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine

HRID 1923284
印刷

反応式

HRID 1923284 の反応式
[CH2:1]([C:3]1[N:7]([C:8]2[N:16]=[C:15]3[C:11]([N:12]=[C:13]([CH:18]=O)[N:14]3[CH3:17])=[C:10]([N:20]3[CH2:25][CH2:24][O:23][CH2:22][CH2:21]3)[N:9]=2)[C:6]2[CH:26]=[CH:27][CH:28]=[CH:29][C:5]=2[N:4]=1)[CH3:2].[CH3:30][S:31]([N:34]1[CH2:39][CH2:38][NH:37][C:36]([CH3:41])([CH3:40])[CH2:35]1)(=[O:33])=[O:32].C(O[BH-](OC(=O)C)OC(=O)C)(=O)C.[Na+]>ClCCCl>[CH3:40][C:36]1([CH3:41])[CH2:35][N:34]([S:31]([CH3:30])(=[O:33])=[O:32])[CH2:39][CH2:38][N:37]1[CH2:18][C:13]1[N:14]([CH3:17])[C:15]2[C:11]([N:12]=1)=[C:10]([N:20]1[CH2:21][CH2:22][O:23][CH2:24][CH2:25]1)[N:9]=[C:8]([N:7]1[C:6]3[CH:26]=[CH:27][CH:28]=[CH:29][C:5]=3[N:4]=[C:3]1[CH2:1][CH3:2])[N:16]=2
参加物実験手順後処理出典と根拠反応ノート

参加物

5

反応物 3

HCID 5049666Sodium triacetoxyborohydrideHCID 198151421-Methanesulfonyl-3,3-dimethylpiperazineHCID 596059872-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde

生成物 1

HCID 596054304-(8-((2,2-dimethyl-4-(methylsulfonyl)piperazin-1-yl)methyl)-2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-9H-purin-6-yl)morpholine収率 13%

試薬・触媒・溶媒 1

HCID 11
1,2-Dichloroethane
溶媒

実験手順

A solution of 2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (167 mg, 0.43 mmol), 1-methanesulfonyl-3,3-dimethylpiperazine (100 mg, 0.52 mmol) and molecular sieves (4 Å, powdered, 830 mg) in DCE (10 mL) was stirred at ambient temperature for 5 h. Sodium triacetoxyborohydride (136 mg, 0.64 mmol) was added and the mixture stirred for 17 h, then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted using 2 M NH3 in MeOH. The product was collected and concentrated in vacuo. The resultant residue was purified by flash chromatography (Si—PPC, DCM:MeOH, 100:0 to 99:1 to 98:2 to 95:5) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine in water on a gradient of acetonitrile 51:49 to 49:51) to afford 596 as a cream foam (31 mg, 13%). LCMS (method I): RT=3.42 min, M+H+=568. 1H NMR (CDCl3, 400 MHz) δ 8.01 (m, 1 H), 7.77 (m, 1 H), 7.26 (m, 2 H), 4.34 (m, 4 H), 3.87 (m, 9 H), 3.36 (q, J=7.5 Hz, 2 H), 3.16 (m, 2 H), 3.02 (s, 2 H), 2.77 (s, 3 H), 2.64 (m, 2 H), 1.46 (t, J=7.5 Hz, 3 H) and 1.29 (s, 6 H)

後処理

  1. washThe cartridge was then washed with methanol
  2. washthe desired product was subsequently eluted
  3. customThe product was collected
  4. concentrationconcentrated in vacuo
  5. customThe resultant residue was purified by flash chromatography (Si—PPC, DCM:MeOH, 100:0 to 99:1 to 98:2 to 95:5)

出典と根拠

ORDレコード
ord-3cf4e73cfbe14b45a81dd98a9c153787
出典データセット
uspto-grants-2012_05
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08173650B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート